BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 19799128)

  • 1. [A quantitative assay for JAK2 mutation in 135 patients with chronic myeloproliferative neoplasms].
    Chao HY; Shen YM; Zhang R; Feng YF; Cen JN; Yao L; Shen HJ; Zhu ZL; Xue YQ
    Zhonghua Xue Ye Xue Za Zhi; 2009 May; 30(5):321-5. PubMed ID: 19799128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The quantitative assay and clinical significance of JAK2V617F mutation in 131 patients with chronic myeloproliferative disorders].
    Shen YM; Chao HY; Zhang R; Feng YF; Cen JN; Yao L; Shen HJ; Zhu ZL; Xue YQ
    Zhonghua Nei Ke Za Zhi; 2009 Feb; 48(2):140-3. PubMed ID: 19549471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].
    Chao HY; Fan Z; Zhang R; Shen YM; Chen W; Fei HR; Zhu ZL; Feng YF; Chen ZX; Xue YQ
    Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):510-4. PubMed ID: 19950698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The clinical implication of JAK2 mutation expression in patients with myeloproliferative disorders].
    Fei HR; Zhang R; Chen SN; Pan JL; Cen JN; Xue YQ
    Zhonghua Nei Ke Za Zhi; 2007 Apr; 46(4):271-3. PubMed ID: 17637260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical study on relationship between JAK2 V617F mutation and chronic myeloproliferative disorders].
    Zhang Y; Li L; Nie L; Yu Y; Yang YH; Zhang ZQ; Yang L; Xu SC; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):105-9. PubMed ID: 18681311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis.
    Vannucchi AM; Pancrazzi A; Bogani C; Antonioli E; Guglielmelli P
    Leukemia; 2006 Jun; 20(6):1055-60. PubMed ID: 16572198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Detection of the JAK2 gene mutation in familial myeloproliferative neoplasm and its clinical significance].
    Zhang YM; Hao LX; Wei Q; Wei YQ; Huang F; Zhang Y; Yin CX; Feng R
    Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):103-7. PubMed ID: 22730657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations in the JAK2 and MPL genes and their correlation to clinical parameters in patients with chronic myeloproliferative disease.
    Bojko P; Abenhardt W; Schnittger S; Haferlach T
    Onkologie; 2009 Apr; 32(4):191-5. PubMed ID: 19372714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
    Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
    J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Detection of JAK2V617F mutation in patients with myeloproliferative disorders with TaqMan-MGB probe].
    Ruan GR; Chen SS; Li LD; Liu YR; Qin YZ; Li JL; Ma X; Wang FR; Jiang Q; Jiang B; Liu KY; Huang XJ
    Zhonghua Yi Xue Za Zhi; 2007 Sep; 87(34):2401-4. PubMed ID: 18036317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates.
    Patnaik MM; Knudson RA; Gangat N; Hanson CA; Pardanani A; Tefferi A; Ketterling RP
    Eur J Haematol; 2010 Jun; 84(6):518-24. PubMed ID: 20331734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The investigation of JAK2 V617F point mutation in myeloproliferative disorders by allele-specific polymerase chain reaction in combination with sequence analysis].
    Zhang SJ; Li WD; Song JH; Xu W; Qiu HX; Li JY
    Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(30):2109-12. PubMed ID: 17988529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of JAK2V617F mutation in Jordanian patients with myeloproliferative neoplasms.
    Jaradat SA; Khasawneh R; Kamal N; Matalka I; Al-Bishtawi M; Al-Sweedan S; Ayesh MH
    Hematol Oncol Stem Cell Ther; 2015 Dec; 8(4):160-6. PubMed ID: 26256826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
    Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
    Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent detection of the JAK2 V617F mutation in bone marrow core biopsy specimens from chronic myeloproliferative disorders using the TaqMan polymerase chain reaction single nucleotide polymorphism genotyping assay: a retrospective study with pathologic correlations.
    Bousquet M; Le Guellec S; Quelen C; Rigal-Huguet F; Delsol G; Brousset P
    Hum Pathol; 2006 Nov; 37(11):1458-64. PubMed ID: 16949922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of JAK2 V617F mutation in Indian patients with chronic myeloproliferative disorders.
    Sazawal S; Bajaj J; Chikkara S; Jain S; Bhargava R; Mahapatra M; Saxena R
    Indian J Med Res; 2010 Oct; 132():423-7. PubMed ID: 20966521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of JAK2(V617F) mutation in Chinese patients with myeloproliferative disorders.
    Chen S; Fei H; Zhang R; Xue Y; Pan J; Wu Y; Ceng J
    Am J Hematol; 2007 Jun; 82(6):458-9. PubMed ID: 17266061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of MPL exon10 mutations in 103 Chinese patients with JAK2V617F-negative myeloproliferative neoplasms.
    Chen X; Qi X; Tan Y; Xu Z; Xu A; Zhang L; Wang H
    Blood Cells Mol Dis; 2011 Jun; 47(1):67-71. PubMed ID: 21555228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
    Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.